Elutia, Inc. · NASDAQ:ELUT
Elutia — Q4 2024 Earnings Presentation
14 slides from Elutia's earnings presentation, Mar 6, 2025
Slide 1: 4th Quarter 2024 Financial Results Call
4th Quarter 2024 Financial Results Call C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer March 6, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation of Elutia Inc. (“Elutia,” “we,” “us,” “our” or the “Company”) (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical fa
Slide 3: Our focused strategy for growth
Pioneering drug-eluting biomatrix technology (DEB) to address complex surgical challenges. Two high-growth proprietary commercial product platforms: CIEDs & Breast Reconstruction Neurostimulators Our focused strategy for growth: 1. Prove the commercial value of EluPro 2. Drive continued growth with
Slide 4: Launching: Now FDA Cleared
Launching Now FDA Cleared ✓ Cardiac Implantable Electronic Devices ✓ Neurostimulators 4
Slide 5: Each year over 600,000 CIEDs are placed in the U.S.
Each year over 600,000 CIEDs are placed in the U.S. Medtronic had the Only Antibiotic Envelope Until now! 40% 60% TYRX Synthetic antibiotic-eluting envelope 5
Slide 6: See why
See why 88% EPs using TYRX polled said they would switch some or all their envelopes to “ Very rough surface.” “ It does not slide easily into the pocket.” “ Reminds me of the ‘no-slip’ coating you sometimes see on garage floors.” 2021+ 2025 Marketing Survey. Data on file. 6
Slide 7: Pilot Launch Goals
Pilot Launch Goals Demonstrate Obtain Drive 1. Operational Excellence 2. Hospital and GOP 3. Clinical Uptake Approvals Business Development Activity: Engaged in strategic discussions with multiple parties 7
Slide 8: Demonstrating Operational Excellence
Demonstrating Operational Excellence • Facility in Roswell, GA for the manufacturing of CanGaroo and EluPro in operation since 2013 with ~75,000 product units produced • Scalable capacity1 to ~$140M of EluPro sales with a target gross margin of >70% • Completed a successful FDA site inspection with
Slide 9: Obtaining Hospital and GPO Approvals
Obtaining Hospital and GPO Approvals • 67 approved EluPro accounts in 2024, averaging ~15 new approvals per month • Now at about 100 actively ordering institutions • Growth supported by contracts with 4 major GPOs Includes Premier & S3P • Additional GPO contract negotiations in progress 9
Slide 10: Drive Clinical Uptake: Expanding
Drive Clinical Uptake Expanding EluPro Nation • First patient implant of EluPro on a CIED device in September • EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands • First patient implant of EluPro on a neurostimulator device in October 10
Slide 11: Drive Clinical Uptake: Efficient Sales Model
Drive Clinical Uptake Efficient STRONG Sales Model: Initial Adoption: • Hybrid model: 12 experienced Elutia • Overall BioEnvelope sales up 18% territory managers, 35 independent reps • EluPro accounted for 30% • The mix of BioEnvelope sales generated of BioEnvelope sales in 4Q from EluPro by our '10
Slide 12: Moving Forward
MOVING FORWARD 1. Drive topline EluPro growth 2. Increase VAC and GPO coverage 3. Initiate EluPro rollout with distribution partner 4. Increase production capacity (and lower COGS) 5. Initiate registry data collection Come Visit us at HRS in San Diego! 12
Slide 13: Financial Update – Q4 2024 vs Q4 2023
Financial Update – Q4 2024 vs Q4 2023 ($ in millions) • Net sales for Device Protection $2.7 vs $2.3 • Net sales of SimpliDerm $2.3 vs $3.0 • Net sales of Cardiovascular products $0.5 vs $0.6 • Overall net sales $5.5 vs. $5.9 • GAAP gross margin 43% vs 36% • Adjusted gross margin1 58% vs 51% • Opera
Slide 14: Questions?
Questions? Its GO time! S) Medicine Humanized”